Abeona Therapeutics Inc.
ABEO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000318306
In the last 90 days, Abeona Therapeutics Inc. insiders filed 1 open-market purchase and 5 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $243.3M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:11 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net income for FY2025: $71.2M (1223.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 17, 2026 | Mar 20, 2025 | Mar 18, 2024 | Mar 29, 2023 | Mar 31, 2022 |
| Revenue | $5.82M | $4.25M | $3.50M | $1.41M | $3.00M |
| Cost of revenue | $1.53M | – | – | – | – |
| Operating expenses | – | $64.2M | $50.6M | $52.3M | $92.8M |
| Research and development | $26.8M | $34.4M | $31.1M | $29.0M | $34.3M |
| Selling, general and administrative | $65.0M | $29.9M | $19.0M | $17.3M | $22.8M |
| Operating income | -$89.4M | -$64.2M | -$47.1M | -$50.9M | -$89.8M |
| Interest expense | $3.74M | $4.21M | $418.0K | $736.0K | $3.67M |
| Income tax | $100.0K | – | – | – | – |
| Net income | $71.2M | -$63.7M | -$54.2M | -$39.7M | -$84.9M |
| EPS, basic | $1.34 | $-1.55 | $-2.53 | $-5.53 | – |
| EPS, diluted | $1.01 | $-1.55 | $-2.53 | – | – |
| Weighted shares, basic | 53.0M | 41.0M | 21.4M | 7.86M | – |
| Weighted shares, diluted | 66.1M | 41.0M | 21.4M | – | – |
| Margins and growth | |||||
| Operating margin | -1536.9% | -1512.3% | -1346.7% | -3600.8% | -2994.5% |
| Net margin | 1223.1% | -1501.0% | -1548.2% | -2807.4% | -2831.2% |
| Revenue growth, year over year | +37.1% | +21.3% | +147.5% | −52.9% | −70.0% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 17, 2026 | Mar 20, 2025 | Mar 18, 2024 | Mar 29, 2023 | Mar 31, 2022 |
| Cash and equivalents | $78.4M | $23.4M | $14.5M | $14.2M | $32.9M |
| Short-term investments | $113.0M | $74.4M | $37.8M | $37.9M | $12.1M |
| Accounts receivable | $6.15M | – | – | – | $3.00M |
| Inventory | $5.49M | – | – | – | – |
| Total current assets | $204.9M | $100.9M | $55.7M | $53.1M | $55.4M |
| Property, plant and equipment | $9.92M | $4.43M | $3.53M | $5.74M | $12.3M |
| Intangible assets | – | – | – | – | $1.38M |
| Total assets | $219.6M | $108.9M | $64.0M | $64.2M | $79.6M |
| Accounts payable | $7.89M | $3.44M | $1.86M | $1.81M | $4.33M |
| Short-term debt | $12.2M | $5.93M | – | – | – |
| Total current liabilities | $29.6M | $16.6M | $13.4M | $7.78M | $16.6M |
| Long-term debt | $7.81M | $13.0M | – | – | – |
| Total liabilities | $60.4M | $64.9M | $49.2M | $37.5M | $28.2M |
| Shareholders' equity | $159.2M | $44.0M | $14.8M | $26.8M | $51.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 17, 2026 | Mar 20, 2025 | Mar 18, 2024 | Mar 29, 2023 | Mar 31, 2022 |
| Operating cash flow | -$76.3M | -$56.0M | -$37.0M | -$43.5M | -$65.7M |
| Capital expenditures | $7.97M | $2.45M | $331.0K | $130.0K | $4.15M |
| Free cash flow | -$84.3M | -$58.5M | -$37.3M | -$43.6M | -$69.8M |
| Depreciation and amortization | $2.55M | $2.00M | $2.29M | $3.09M | $3.25M |
| Stock-based compensation | $10.8M | $6.63M | $4.77M | $3.05M | $5.25M |
| Investing cash flow | $105.0M | -$39.2M | $208.0K | -$24.0M | $66.1M |
| Financing cash flow | $26.0M | $104.1M | $37.1M | $43.2M | $24.9M |
| Net change in cash | $54.7M | $8.88M | $256.0K | -$24.3M | $25.3M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 185.2% | 156.1% | 136.2% | 215.8% | 175.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 5, 2026 | 57.1M | +5.5% | SEC |
| Aug 10, 2026 | 57.2M | +11.5% | SEC |
| May 8, 2026 | 57.0M | +11.4% | SEC |
| Mar 11, 2026 | 57.0M | +17.5% | SEC |
| Nov 7, 2025 | 54.2M | +24.7% | SEC |
| Aug 8, 2025 | 51.3M | +18.4% | SEC |
| May 9, 2025 | 51.2M | +24.2% | SEC |
| Mar 11, 2025 | 48.5M | +77.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-25 in Q3 2022.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.